Allergan, Inc. v. Sandoz Inc, No. 2:09-cv-00097 (E.D. Tex. Jan. 5, 2010)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Pending before the court is Defendant Sandoz Inc.’s (“Sandoz”) Motion to Strike Plaintiff’s Jury Demand. [Dkt. No. 34] Having considered the parties’ motions and arguments, the Court is of the opinion that the motion should be DENIED. Plaintiff Allergan, Inc. (“Allergan”) brought this action is response to Sandoz’s submission of an Abbreviated New Drug Application (“AND A”) for approval of a generic version of Allergan’s COMBIGAN drug.